[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100655983":3},{"organization":4,"outcomesModule":7,"designInfo":36,"detailedDescription":39,"studyPopulation":40,"armGroups":41,"interventions":35,"overallOfficials":45,"centralContacts":50,"locations":35,"responsibleParty":56,"collaborators":35,"id":60,"slug":61,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":35,"eligibilityCriteria":66,"healthyVolunteers":62,"sex":67,"minAge":68,"maxAge":35,"enrollmentInfo":69,"targetDuration":72,"studyType":73,"phases":35,"briefSummary":74,"conditions":75,"keywords":79,"overallStatus":86,"whyStopped":35,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":35},{"fullName":5,"class":6},"Assiut University","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":35},[9],{"measure":10,"description":11,"timeFrame":12},"Prevalence of secondary hyperparathyroidism","Proportion of patients with elevated intact parathyroid hormone (iPTH) levels above the target range (greater than 9 times the upper limit of normal) among regular hemodialysis patients.","Baseline",[14,17,20,23,26,29,32],{"measure":15,"description":16,"timeFrame":12},"Prevalence of adequate dialysis","Proportion of patients achieving target dialysis adequacy defined as single-pool Kt\u002FV (spKt\u002FV) ≥ 1.2 or urea reduction ratio (URR) ≥ 65%.",{"measure":18,"description":19,"timeFrame":12},"Correlation between dialysis adequacy and iPTH level","Correlation coefficient between dialysis adequacy parameters (spKt\u002FV and URR) and serum intact parathyroid hormone (iPTH) levels, using Spearman or Pearson correlation as appropriate.",{"measure":21,"description":22,"timeFrame":12},"Serum phosphate levels according to dialysis adequacy","Mean serum phosphate concentration (mg\u002FdL) in patients with adequate versus inadequate dialysis.",{"measure":24,"description":25,"timeFrame":12},"Serum calcium level","Mean serum calcium concentration (mg\u002FdL) in patients with secondary hyperparathyroidism.",{"measure":27,"description":28,"timeFrame":12},"Serum phosphate level","Mean serum phosphate concentration (mg\u002FdL) in patients with secondary hyperparathyroidism.",{"measure":30,"description":31,"timeFrame":12},"Serum alkaline phosphatase level","Mean serum alkaline phosphatase concentration (U\u002FL) in patients with secondary hyperparathyroidism.",{"measure":33,"description":34,"timeFrame":12},"Calcium-phosphorus product","Mean calcium-phosphorus product (mg²\u002FdL²) in patients with secondary hyperparathyroidism.",null,{"allocation":35,"interventionModel":35,"interventionModelDescription":35,"primaryPurpose":35,"observationalModel":37,"timePerspective":38,"maskingInfo":35},"CASE_ONLY","CROSS_SECTIONAL","Secondary hyperparathyroidism is a common complication of end-stage renal disease and is associated with bone disease, vascular calcification, and increased mortality. Dialysis adequacy, measured by spKt\u002FV and urea reduction ratio (URR), may influence phosphate control and parathyroid hormone levels.\n\nThis observational cross-sectional study will include adult patients with end-stage renal disease maintained on regular thrice-weekly hemodialysis for at least three months. Dialysis adequacy will be assessed by spKt\u002FV and URR. Serum intact parathyroid hormone (iPTH) and mineral parameters will be measured.","Adult patients with end-stage renal disease maintained on regular thrice-weekly hemodialysis for at least three months at the Hemodialysis Unit, Nephrology Department, Assiut University Hospitals.",[42],{"label":43,"type":35,"description":44,"interventionNames":35},"Single cohort: ESRD patients on regular hemodialysis","Adult patients with end-stage renal disease on regular thrice-weekly hemodialysis who will undergo assessment of dialysis adequacy (spKt\u002FV and URR) and measurement of serum intact parathyroid hormone and mineral parameters.",[46],{"name":47,"affiliation":48,"role":49},"Salma M Osman, prof","Internal Medicine Department, Assiut University Hospitals","STUDY_CHAIR",[51],{"name":52,"role":53,"phone":54,"phoneExt":35,"email":55},"Lamia A fathey, Resident","CONTACT","+20 11 00530550","lamiaaabdellah62@gmail.com",{"type":57,"investigatorFullName":58,"investigatorTitle":59,"investigatorAffiliation":5,"oldNameTitle":35,"oldOrganization":35},"PRINCIPAL_INVESTIGATOR","Lamia Abdallah fathey","Resident Physician","100655983","hyperparathyroidism-and-dialysis-adequacy-in-hemodialysis-patients-100655983",false,"NCT07820150","Hyperparathyroidism and Dialysis Adequacy in Hemodialysis Patients","Prevalence of Hyperparathyroidism Among End-Stage Renal Disease Patients on Regular Hemodialysis and Its Relation to Dialysis Adequacy","Inclusion Criteria:\n\n* \\- Age 18 years or older\n* Diagnosed with end-stage renal disease\n* Maintained on regular thrice-weekly hemodialysis for at least three consecutive months\n* Written informed consent\n\nExclusion Criteria:\n\n* \\- Primary hyperparathyroidism or prior parathyroidectomy\n* Active severe infections or acute systemic illnesses\n* Active malignancy\n* Severe hepatic dysfunction or chronic liver cirrhosis","ALL","18 Years",{"count":70,"type":71},130,"ESTIMATED","1 Day","OBSERVATIONAL","This cross-sectional study aims to determine the prevalence of secondary hyperparathyroidism among end-stage renal disease patients on regular hemodialysis and to evaluate its relationship with dialysis adequacy at Assiut University Hospitals.",[76,77,78],"Hyperparathyroidism, Secondary","Kidney Failure, Chronic","Chronic Kidney Diseases",[80,81,82,83,84,85],"Secondary hyperparathyroidism","Dialysis adequacy","Hemodialysis","Kt\u002FV","iPTH","Assiut","NOT_YET_RECRUITING","2026-09-11",{"date":89,"type":90},"2026-09-15","ACTUAL",{"date":92,"type":71},"2026-09-10",{"date":94,"type":71},"2028-03-01",{"name":5,"class":6}]